

Best Practice Protocol for the Blue Cross Blue Shield of Michigan Cardiovascular Consortium

# ARTERIAL ACCESS FOR INVASIVE CARDIOVASCULAR PROCEDURES

Version - 2/25/2021

## **Trans Radial Artery (TRA) Access**

#### Pre-procedure considerations:

rie-procedure consid	
Planned use of RA as	<ul> <li>There is a signal for higher graft failure with prior TRA access (1)</li> </ul>
vascular conduit:	<ul> <li>While this needs further exploration, at present would recommend</li> </ul>
CKD/ESRD, RA graft	patient-specific risk/benefit assessment for TRA, especially in
for CABG	presence of already existing RA occlusion (RAO)
	<ul> <li>Use of TRA in patients with ESRD is associated with lower</li> </ul>
	bleeding vs. TFA (BMC2 data)(2)
Right vs. Left RA	<ul> <li>Consider using LEFT RA if:</li> </ul>
	<ul> <li>Short stature (&lt;5'3"), female gender</li> </ul>
	○ Age > 75
	<ul> <li>Presence of LIMA graft</li> </ul>
Allen's/Barbeau	<ul> <li>Useful for use in identifying unilateral radial artery occlusion, prompting</li> </ul>
Testing	contralateral RA or ipsilateral ulnar cannulation
	<ul> <li>There is growing data to support the use of TRA in patients with</li> </ul>
	abnormal Allen's/Barbeau testing (3)
Prior Imaging	<ul> <li>If present, review prior chest imaging (angiography, CT, ultrasonography)</li> </ul>
	or catheterization for anatomic considerations that may influence access
	strategy
	<ul> <li>i.e. aberrant innominate insertion, upper extremity occlusive</li> </ul>
	disease, known radial loop/occlusion, aberrant insertion of RA,
	prominent recurrent radial
Hemodynamic	<ul> <li>Choosing spasmolytic: severe or critical aortic stenosis, severely</li> </ul>
considerations	decompensated heart failure
	<ul> <li>Using ultrasound guidance: significant hypotension, PAD</li> </ul>
	<ul> <li>STEMI, Shock: TRA safe and effective</li> </ul>
Anticoagulation status	<ul> <li>Reasonable to perform transradial angiography and elective PCI in the</li> </ul>
5	presence of therapeutic anticoagulation with warfarin (4, 5)
	<ul> <li>While there is data to support TRA in setting of therapeutic</li> </ul>
	anticoagulation with warfarin, we would recommend <i>patient</i> -
	specific risk/benefit assessment of interrupting anticoagulation
	prior to procedure
	<ul> <li>DOACs: Further exploration necessary to confirm safety, efficacy (6)</li> </ul>
RA pulse	<ul> <li>If not readily palpable, <u>ultrasound guidance</u> should be considered to assist</li> </ul>
	cannulation(7)

1

......

. . . . . . . . . . . . . . . . . .

### Access Technique + Cannulation:

Arterial Puncture	• Single (modified Seldinger) or double wall (true) techniques:
	<ul> <li>Similar success and similar rates of complications'</li> </ul>
	<ul> <li>Double wall (true Seldinger) with higher "1<sup>st</sup> pass" success (8)</li> </ul>
Sheath	<ul> <li>Smallest caliber sheath necessary: reduces risk of RAO</li> </ul>
	• Hydrophilic coating: improved patient comfort, lower rates of RA spasm
Antispasmolytic	<ul> <li>No single optimal agent, most investigations have been of calcium</li> </ul>
-intra-arterial	channel blockers and nitrates.
	<ul> <li>Verapamil (IA): 2.5mg or 5mg of verapamil</li> </ul>
	<ul> <li>Nitroglycerin (IA): 100-200mcg of nitroglycerin</li> </ul>
	<ul> <li>combination of both</li> </ul>
	<ul> <li>Special circumstances: avoid Ntg in setting of critical AS, avoid</li> </ul>
	verapamil in severe decompensated heart failure
Anticoagulation	• There is ongoing uncertainty for the optimal initial dose of anticoagulant
	to balance risk of RAO and bleeding
	<ul> <li>Dosing: at least 50u/kg (or 5000u) of unfractionated heparin (or</li> </ul>
	equivalent dosing for bivalirudin)
	<ul> <li>Recent data supports the use of 70-100 U/kg (in divided doses at</li> </ul>
	the time of sheath insertion and removal), with less RAO (9) but
	with prolonged time to hemostasis
	<ul> <li>Intravenous and Intra-arterial administration with similar efficacy</li> </ul>
Hemostasis	• Focus is on <i>patent hemostasis</i> : achieving a balance between
	maintenance of radial artery flow and arteriotomy hemostasis.
	<ul> <li>After application of radial compression device and achieving</li> </ul>
	hemostasis, confirm ongoing RA patency with ulnar occlusion (Barbeau)
	• No consensus for compression duration: consensus recommendations
	of 60 min. after diagnostic angiography, 120 min. after PCI (10)



## Femoral Artery (FA) Access

### Pre-procedure considerations:

.....

Consider use of TRA	<ul> <li>Preponderance of data supports use of a transradial approach over transfemoral for patient safety, comfort, and costs</li> <li>Recent data with contemporary femoral access techniques suggest outcomes similar to RA can be achieved in STEMI (11)</li> </ul>
Prior Imaging	<ul> <li>If present, review prior femoral imaging (angiography, CT, ultrasonography) or catheterization for anatomic considerations that may influence access strategy</li> </ul>
Prior revascularization	<ul> <li>Consider access strategy in the presence of prior iliofemoral revascularizations:         <ul> <li>Endovascular: Iliofemoral stenting</li> <li>Surgical: aortofemoral, fem-fem bypass, femoral endarterectomy</li> </ul> </li> </ul>
Anticoagulation status	<ul> <li>For elective cases, recommend alternative access approach or deferral for patients on therapeutic anticoagulation with either(12):         <ul> <li>Warfarin (INR&gt;1.7 within 24h of procedure)</li> <li>DOAC</li> </ul> </li> </ul>



#### Access technique:

.....

. .

Access lecinique.	
Guidance: Combination of fluoroscopy and	<ul> <li>We recommend a combination of fluoroscopic and ultrasonographic guidance for femoral access</li> </ul>
ultrasonography	<ul> <li>Fluoroscopy: establish compressible site for arteriotomy</li> <li>establish superior and inferior borders of femoral head using radiopaque marker (i.e. Kelly clamp)</li> <li>Ensure gantry oriented over femoral head, minimizing parallax</li> </ul>
	<ul> <li>Ultrasonography: identify anatomic landmarks and guide needle entry</li> <li>Superior: identify posterior dive of vessel and inferior epigastric artery, identifying entry into pelvis</li> <li>Inferior: bifurcation into SFA and profunda femoris</li> <li>Common femoral: identify optimal site for arterial puncture, above bifurcation and below pelvic transition,         <ul> <li>correlate w/fluoro-obtained femoral head position</li> <li>Avoid significant plaque or calcification that may compromise access/hemostasis</li> <li>Under ultrasonographic guidance, advance needle to anterior wall and puncture in <i>modified</i> Seldinger technique.</li> <li>Puncture site <i>should be visualized within</i> ultrasound plane to ensure optimal position of arteriotomy.</li> <li>Ultrasonographic guidance <i>especially helpful</i> in obese patients or those with obscured or distorted anatomic landmarks</li> </ul> </li> </ul>
Needle Choice	<ul> <li>Micropuncture (21g) systems should be considered over standard (18g) systems for femoral arterial puncture.</li> <li>use of micropuncture for access associated with reduced vascular complications compared with standard 18g (13)</li> </ul>
Arterial imaging	<ul> <li>In elective cases, angiographic imaging of the arteriotomy via sheath recommended prior to initiation of anticoagulation, and in all cases prior to deployment of a vascular closure device (12)         <ul> <li>Position gantry ~30 degrees <i>ipsilateral oblique</i> to arteriotomy to splay out bifurcation</li> <li>perform sideport angiography to identify any procedure-related complication/arteriotomy position prior to use of anticoagulation or vascular closure device (VCD).</li> <li>To minimize risk of hydraulic iliac dissection, either assess sideport pressure waveform or advance wire through sheath prior to injection</li> </ul> </li> </ul>
Hemostasis	<ul> <li>There is no definitive data to support the use of VCDs to reduce femoral complications over manual compression alone         <ul> <li>VCDs can reduce time to ambulation but should be deployed consistent with device-specific instruction for use</li> <li>There is an association between VCD use and reduced bleeding in obese patients (BMC2 data)(14)</li> </ul> </li> <li>For manual compression in patients with therapeutic anticoagulation, recommend waiting until ACT &lt; 180s before sheath pull (12)</li> </ul>



### References

1. Kamiya H, Ushijima T, Kanamori T, et al. Use of the radial artery graft after transradial catheterization: is it suitable as a bypass conduit? Ann Thorac Surg 2003;76:1505–1509.

2. Sutton NR, Seth M, Lingam N, Gurm HS. Radial Access Use for Percutaneous Coronary Intervention in Dialysis Patients. Circ Cardiovasc Interv 2020;13:e008418.

3. van Leeuwen MAH, Hollander MR, van der Heijden DJ, et al. The ACRA Anatomy Study (Assessment of Disability After Coronary Procedures Using Radial Access): A Comprehensive Anatomic and Functional Assessment of the Vasculature of the Hand and Relation to Outcome After Transradial Catheterization. Circ Cardiovasc Interv 2017;10.

4. Baker NC, O'Connell EW, Htun WW, et al. Safety of coronary angiography and percutaneous coronary intervention via the radial versus femoral route in patients on uninterrupted oral anticoagulation with warfarin. Am Heart J 2014;168:537–544.

5. Ahmed I, Gertner E, Zhu WNCH& D. Safety of coronary angiography and percutaneous coronary intervention in patients on uninterrupted warfarin therapy: a meta-analysis. Interventional Cardiology 2011;3:101–109.

6. Chongprasertpon N, Zebrauskaite A, Coughlan JJ, et al. Performing diagnostic radial access coronary angiography on uninterrupted direct oral anticoagulant therapy: a prospective analysis. Open Heart 2019;6:e001026.

7. Moussa Pacha H, Alahdab F, Al-Khadra Y, et al. Ultrasound-guided versus palpationguided radial artery catheterization in adult population: A systematic review and metaanalysis of randomized controlled trials. Am Heart J 2018;204:1–8.

8. Pancholy SB, Sanghvi KA, Patel TM. Radial artery access technique evaluation trial: randomized comparison of Seldinger versus modified Seldinger technique for arterial access for transradial catheterization. Catheter Cardiovasc Interv 2012;80:288–291.

9. Hahalis GN, Leopoulou M, Tsigkas G, et al. Multicenter Randomized Evaluation of High Versus Standard Heparin Dose on Incident Radial Arterial Occlusion After Transradial Coronary Angiography: The SPIRIT OF ARTEMIS Study. JACC Cardiovasc Interv 2018;11:2241–2250.

10. Mason PJ, Shah B, Tamis-Holland JE, et al. An Update on Radial Artery Access and Best Practices for Transradial Coronary Angiography and Intervention in Acute Coronary Syndrome: A Scientific Statement From the American Heart Association. Circ Cardiovasc Interv 2018;11:e000035.



11. Le May M, Wells G, So D, et al. Safety and Efficacy of Femoral Access vs Radial Access in ST-Segment Elevation Myocardial Infarction: The SAFARI-STEMI Randomized Clinical Trial. JAMA Cardiol 2020;5:126–134.

12. Naidu SS, Aronow HD, Box LC, et al. SCAI expert consensus statement: 2016 best practices in the cardiac catheterization laboratory: (Endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologia intervencionista; Affirmation of value by the Canadian Association of interventional cardiology-Association canadienne de cardiologie d'intervention). Catheter Cardiovasc Interv 2016;88:407–423.

13. Ben-Dor I, Sharma A, Rogers T, et al. Micropuncture technique for femoral access is associated with lower vascular complications compared to standard needle. Catheter Cardiovasc Interv 2020.

14. Gurm HS, Hosman C, Share D, Moscucci M, Hansen BB. Comparative safety of vascular closure devices and manual closure among patients having percutaneous coronary intervention. Annals of internal medicine 2013;159:660–6.

Acknowledgements – Javier Valle (lead author), Edouard Daher, Hitinder Gurm, Ryan Madder, Devraj Sukul, Michael Tucciarone, and Anwar Zaitoun

BMC2 Best Practice Protocols are based on consortium-wide consensus at the time of publication. Protocols will be updated regularly, and should not be considered formal guidance, and do not replace the professional opinion of the treating physician.



**BMC2** 2929 Plymouth Road, Suite 225 Ann Arbor, MI 48105 (734) 998-6400

Support for BMC2 is provided by Blue Cross and Blue Shield of Michigan and Blue Care Network as part of the BCBSM Value Partnerships program. Although Blue Cross Blue Shield of Michigan and BMC2 work collaboratively, the opinions, beliefs and viewpoints expressed by the author do not necessarily reflect the opinions, beliefs and viewpoints of BCBSM or any of its employees.